BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
U.S. to drop childhood vaccine recommendations as it looks to Denmark, Washington Post reports - 2Arctic is again the hottest it's been in 125 years, with record-low sea ice, NOAA report says
- 3The most effective method to Beat Dental Tension and Guarantee Customary Exams
- 4Family Holiday spots
- 5Most loved Occasion Dish: What Makes Your Merry Table?
- Netanyahu leads meeting on West Bank riots, Katz defends axing administrative detention for Jews
- A Concise History Of The Entertainment world
- Kona SUV: Exploring the Future with Hyundai's Visionary Hybrid
- 5 VIPs That Changed Style
- Manual for 6 Busssiness Class Flights
- Manual for Tracking down Spending plan Agreeable Travel Objections
- Story of ‘first Black Briton’ rewritten by advances in ancient DNA technology
- Which Brilliant Home Gadget Can't You Reside Without?
- 7 Logically Demonstrated Techniques for Better Rest
